Trial Profile
Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2016
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
- 15 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 18 Aug 2012 Status changed from suspended to recruiting as reported by University of Southern California Norris Comprehensive Cancer Center.
- 29 Apr 2012 Status changed from recruiting to suspended as reported by University of Southern California Norris Comprehensive Cancer Center.